- Home
- BSM vs XENE Comparison
BSM vs XENE Comparison
Compare BSM & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- XENE
- Stock Information
- Founded
- BSM 1876
- XENE 1996
- Country
- BSM United States
- XENE Canada
- Employees
- BSM N/A
- XENE N/A
- Industry
- BSM Oil & Gas Production
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- BSM Energy
- XENE Health Care
- Exchange
- BSM Nasdaq
- XENE Nasdaq
- Market Cap
- BSM 3.1B
- XENE 2.5B
- IPO Year
- BSM 2015
- XENE 2014
- Fundamental
- Price
- BSM $13.64
- XENE $30.29
- Analyst Decision
- BSM Hold
- XENE Strong Buy
- Analyst Count
- BSM 2
- XENE 11
- Target Price
- BSM $14.00
- XENE $54.82
- AVG Volume (30 Days)
- BSM 325.8K
- XENE 1.2M
- Earning Date
- BSM 05-05-2025
- XENE 05-12-2025
- Dividend Yield
- BSM 11.00%
- XENE N/A
- EPS Growth
- BSM N/A
- XENE N/A
- EPS
- BSM 0.92
- XENE N/A
- Revenue
- BSM $422,061,000.00
- XENE $7,500,000.00
- Revenue This Year
- BSM $13.21
- XENE N/A
- Revenue Next Year
- BSM $7.04
- XENE $1,553.36
- P/E Ratio
- BSM $14.83
- XENE N/A
- Revenue Growth
- BSM N/A
- XENE N/A
- 52 Week Low
- BSM $12.80
- XENE $26.74
- 52 Week High
- BSM $16.48
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- BSM 39.95
- XENE 35.11
- Support Level
- BSM $13.45
- XENE $29.21
- Resistance Level
- BSM $14.08
- XENE $36.96
- Average True Range (ATR)
- BSM 0.26
- XENE 1.63
- MACD
- BSM -0.03
- XENE -0.90
- Stochastic Oscillator
- BSM 16.03
- XENE 17.03
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.